Free tool
Drug Trial Radar: Rare and genetic disease
Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
30
Completed, industry sponsors, Rare and genetic disease, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
30 trials
Showing 1 to 25, recently updated first.
- Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to PalynziqCompleted
BioMarin PharmaceuticalBioMarin (BMRN)
NCT06780332 · 9 participants · Start Feb 7, 2025 · Primary completion Aug 17, 2026
Drug: RDD to Palynziq · For: Phenylketonuria; PKU
Sites: Chevy Chase, Maryland
ShireTakeda (TAK)
NCT02455622 · 21 participants · Start Oct 28, 2015 · Primary completion Jul 29, 2025
Drug: Elaprase for intravenous (IV) infusion · For: Hunter Syndrome
Sites: Chicago, Illinois; Santo Domingo, Dominican Republic; Mainz, Germany · 8 sites in all
- A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of FabrazymeCompleted
SanofiSanofi (SNY)
NCT06019728 · 8 participants · Start Nov 10, 2023 · Primary completion Oct 25, 2024
Drug: AGALSIDASE BETA (GZ419828); Acetaminophen and 6 more · For: Fabry's Disease
Sites: Santa Monica, California; Atlanta, Georgia; Grand Rapids, Michigan · 5 sites in all
Genzyme, a Sanofi CompanySanofi (SNY)
NCT05134571 · 12 participants · Start Oct 28, 2021 · Primary completion Jul 26, 2023
Drug: Laronidase · For: Mucopolysaccharidosis I
Sites: Beijing, China; Guangzhou, China; Hangzhou, China · 5 sites in all
SanofiSanofi (SNY)
NCT04656600 · 12 participants · Start Mar 2, 2021 · Primary completion Oct 12, 2023
Drug: Cerezyme® / Imiglucerase · For: Gaucher's Disease
Sites: Beijing, China; Chengdu, China; Guangzhou, China · 5 sites in all
Genzyme, a Sanofi CompanySanofi (SNY)
NCT05054387 · 22 participants · Start Oct 13, 2021 · Primary completion Mar 9, 2023
Drug: Agalsidase beta · For: Fabry Disease
Sites: Beijing, China; Shanghai, China; Taiyuan, China · 6 sites in all
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT03910621 · 17 participants · Start Apr 2, 2020 · Primary completion Mar 25, 2022
Drug: Miglustat · For: Niemann-Pick Disease, Type C
Sites: Beijing, China; Shanghai, China
Genzyme, a Sanofi CompanySanofi (SNY)
NCT04676373 · 41 participants · Start Mar 10, 2021 · Primary completion Jul 25, 2024
Drug: ALGLUCOSIDASE ALFA · For: Pompe's Disease
Sites: China, China
- A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in IndiaCompleted
TakedaTakeda (TAK)
NCT05058391 · 5 participants · Start Apr 21, 2022 · Primary completion Apr 6, 2024
Drug: Elaprase · For: Hunter Syndrome
Sites: Thiruvananthapuram, India; Jaipur, India; Kolkata, India · 5 sites in all
BioMarin PharmaceuticalBioMarin (BMRN)
NCT01965912 · 34 participants · Start Oct 2013 · Primary completion Jan 4, 2023
Drug: Kuvan® · For: Phenylketonuria
Sites: Munich, Germany; Münster, Germany; Bologna, Italy · 12 sites in all
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00486889 · 12 participants · Start Aug 26, 2008 · Primary completion Nov 23, 2021
Drug: alglucosidase alfa · For: Pompe Disease; Glycogen Storage Disease Type II (GSD-II); Acid Maltase Deficiency Disease
Sites: Gainesville, Florida; Decatur, Georgia; Detroit, Michigan
Genzyme, a Sanofi CompanySanofi (SNY)
NCT03687333 · 10 participants · Start Dec 4, 2018 · Primary completion Dec 30, 2020
Drug: ALGLUCOSIDASE ALFA (MYOZYME) · For: Glycogen Storage Disease Type II
Sites: Shanghai, China
Genzyme, a Sanofi CompanySanofi (SNY)
NCT01410890 · 21 participants · Start Nov 3, 2014 · Primary completion Nov 20, 2020
Drug: alglucosidase alfa · For: Pompe Disease; Glycogen Storage Disease Type II (GSD II)
Sites: Valhalla, New York; Cincinnati, Ohio; Salt Lake City, Utah · 12 sites in all
ShireTakeda (TAK)
NCT02574286 · 21 participants · Start Jun 29, 2016 · Primary completion Nov 12, 2020
Drug: Velaglucerase alfa · For: Gaucher Disease
Sites: Beverly Hills, California; Los Angeles, California; Atlanta, Georgia · 15 sites in all
ShireTakeda (TAK)
NCT00607386 · 28 participants · Start Dec 31, 2007 · Primary completion Jul 8, 2011
Drug: Idursulfase · For: Hunter Syndrome; Mucopolysaccharidosis II; MPS II
Sites: Porto Alegre, Brazil; Warsaw, Poland; Taipei, Taiwan
PfizerPfizer (PFE)
NCT01132690 · 11 participants · Start Aug 2010 · Primary completion May 2012
Drug: Taliglucerase alfa · For: Gaucher Disease
Sites: Jerusalem, Israel; Barrio Sajonia Asunción, Paraguay; Morningside, South Africa
- A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry DiseaseCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00140621 · 6 participants · Start Jul 2005 · Primary completion Aug 2012
Drug: Agalsidase beta · For: Fabry Disease
Sites: Aichi, Japan; Hokkaido, Japan; Kagoshima, Japan · 7 sites in all
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00144781 · 34 participants · Start Dec 2004 · Primary completion Jan 2006
Drug: Aldurazyme (Recombinant Human Alpha-L-Iduronidase); Aldurazyme (Recombinant Human Alpha-L-Iduronidase) and 2 more · For: Mucopolysaccharidosis I; Hurler's Syndrome; Hurler-Scheie Syndrome and 1 more
Sites: Florianópolis, Brazil; Belo Horizonte, Brazil; Porto Alegre, Brazil · 5 sites in all
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00364858 · 95 participants · Start Dec 2001
Drug: Cerezyme · For: Gaucher Disease, Type 1; Cerebroside Lipidosis Syndrome; Glucocerebrosidase Deficiency Disease and 2 more
Sites: Washington D.C., District of Columbia; Coral Springs, Florida; Atlanta, Georgia · 26 sites in all
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00081497 · 67 participants · Start Jan 2004 · Primary completion Sep 2005
Drug: agalsidase beta · For: Fabry Disease
Sites: Birmingham, Alabama; Los Angeles, California; San Francisco, California · 25 sites in all
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00365131 · 40 participants · Start Dec 1997
Drug: Cerezyme (imiglucerase for injection) · For: Gaucher Disease Type I; Cerebroside Lipidosis Syndrome; Clucocerebrosidase Deficiency Disease and 2 more
Sites: Coral Springs, Florida
Genzyme, a Sanofi CompanySanofi (SNY)
NCT01288027 · 16 participants · Start Jun 2011 · Primary completion Dec 2013
Drug: Alglucosidase Alfa · For: Pompe Disease (Late-Onset); Glycogen Storage Disease Type II (GSD II); Glycogenesis 2 Acid Maltase Deficiency
Sites: Orange, California; Gainesville, Florida; Kansas City, Kansas · 15 sites in all
Genzyme, a Sanofi CompanySanofi (SNY)
NCT01650779 · 15 participants · Start Apr 2012 · Primary completion Mar 2013
Drug: Agalsidase beta · For: Fabry Disease
Sites: Coral Springs, Florida; Decatur, Georgia; Baltimore, Maryland · 6 sites in all
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00701129 · 4 participants · Start Oct 2009 · Primary completion Mar 2013
Drug: Alglucosidase Alfa; Methotrexate and 1 more · For: Pompe Disease; Glycogen Storage Disease Type II
Sites: Louisville, Kentucky; Durham, North Carolina
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00144768 · 25 participants (planned) · Start Jul 2004 · Primary completion May 2007
Drug: laronidase · For: Mucopolysaccharidosis I; Hurler's Syndrome; Hurler-Scheie Syndrome and 1 more
Sites: Los Angles, California; Hartford, Connecticut; Milwaukee, Wisconsin
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.